Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA H1047R |
| Therapy | Dactolisib + Navitoclax |
| Indication/Tumor Type | colorectal cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047R | colorectal cancer | sensitive | Dactolisib + Navitoclax | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of dactolisib and Navitoclax (ABT-263) resulted in greater growth inhibition compared to either agent alone in murine-derived colorectal cancer organoids harboring PIK3CA H1047R in culture (PMID: 40635161). | 40635161 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40635161) | BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer. | Full reference... |